Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups

Cancer Cell

Volumn 34, Issue 3, 2018, Pages 396-410.e8

  Archer, Tenley C ^a,b,c   Ehrenberger, Tobias ^d   Mundt, Filip ^c,e   Gold, Maxwell P ^d   Krug, Karsten ^c   Mah, Clarence K ^f   Mahoney, Elizabeth L ^a,b   Daniel, Colin J ^g   LeNail, Alexander ^d   Ramamoorthy, Divya ^d   Mertins, Philipp ^c,o,p   Mani, D R ^c   Zhang, Hailei ^c   Gillette, Michael A ^b,c,h   Clauser, Karl ^c   Noble, Michael ^c   Tang, Lauren C ^c   Pierre François, Jessica ^a,b   Silterra, Jacob ^c   Jensen, James ^f   Tamayo, Pablo ^f,i   Korshunov, Andrey ^j,k   Pfister, Stefan M ^j,l,m   Kool, Marcel ^j,l   Northcott, Paul A ^j,n   Sears, Rosalie C ^g   Lipton, Jonathan O ^a,b   Carr, Steven A ^c   Mesirov, Jill P ^f,i   Pomeroy, Scott L ^a,b,c   Fraenkel, Ernest ^c,d   more..

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d Massachusetts Institute of Technology Cambridge   (United States)

^e KAROLINSKA INSTITUTE   (Sweden)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^j GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^k UNIVERSITY OF HEIDELBERG   (Germany)

^l Preclinical Program   (Germany)

^m UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

ⁿ ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^o MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^p BERLIN INSTITUTE OF HEALTH   (Germany)

more..

Author keywords

mass spectrometry; medulloblastoma; multi omics; MYC; network integration; NU 7441; phospho proteomics; proteo genomics; radio sensitization; SHH

Indexed keywords

CALCIUM; CAMK2G PROTEIN; CAMK4 PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIN DEPENDENT KINASE 2; DGKI PROTEIN; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE; GLYCOGEN SYNTHASE KINASE 3BETA; GLYCOGEN SYNTHASE KINASE B; MITOGEN ACTIVATED PROTEIN KINASE 1; MYC PROTEIN; NOTCH1 RECEPTOR; PHOSPHOTRANSFERASE; PIK3CA PROTEIN; PIK3R1 PROTEIN; PRKACB PROTEIN; PRKCA PROTEIN; PRKDC PROTEIN; PROTEIN; PROTEIN KINASE C; PROTEIN P53; PROTEOME; RAS PROTEIN; RIBOSOMAL PROTEIN KINASE 6; RIBOSOME PROTEIN; RNA; UNCLASSIFIED DRUG; DNA DEPENDENT PROTEIN KINASE; MYC PROTEIN, HUMAN; NUCLEAR PROTEIN; PRKDC PROTEIN, HUMAN; SHH PROTEIN, HUMAN; SONIC HEDGEHOG PROTEIN; TUMOR MARKER;

ARTICLE; CANCER SURVIVAL; ENZYME ACTIVITY; GENETIC HETEROGENEITY; IC50; IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY; IMMUNOFLUORESCENCE; MEDULLOBLASTOMA; MEDULLOBLASTOMA CELL LINE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEOMICS; RNA SEQUENCE; TREATMENT OUTCOME; WESTERN BLOTTING; WHOLE GENOME SEQUENCING; ADOLESCENT; ADULT; BRAIN TUMOR; CHILD; DNA METHYLATION; FEMALE; GENE EXPRESSION PROFILING; HUMAN; INFANT; MALE; METABOLISM; PATHOLOGY; PRESCHOOL CHILD; SEQUENCE ANALYSIS; TUMOR CELL LINE; YOUNG ADULT;

ADOLESCENT; ADULT; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; DNA METHYLATION; DNA-ACTIVATED PROTEIN KINASE; FEMALE; GENE EXPRESSION PROFILING; HEDGEHOG PROTEINS; HUMANS; INFANT; MALE; MEDULLOBLASTOMA; NUCLEAR PROTEINS; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEOME; PROTEOMICS; PROTO-ONCOGENE PROTEINS C-MYC; SEQUENCE ANALYSIS, RNA; YOUNG ADULT;

EID: 85052155527     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2018.08.004     Document Type: Article

References (85)

1. An, J., Yang, D.Y., Xu, Q.Z., Zhang, S.M., Huo, Y.Y., Shang, Z.F., Wang, Y., Wu, D.C., Zhou, P.K., DNA-dependent protein kinase catalytic subunit modulates the stability of c-Myc oncoprotein. Mol. Cancer, 7, 2008, 32.
2. Arcella, A., Carpinelli, G., Battaglia, G., D'Onofrio, M., Santoro, F., Ngomba, R.T., Bruno, V., Casolini, P., Giangaspero, F., Nicoletti, F., Pharmacological blockade of group II metabotropic glutamate receptors reduces the growth of glioma cells in vivo. Neuro Oncol. 7 (2005), 236–245.
3. Archer, T.C., Jin, J., Casey, E.S., Interaction of Sox1, Sox2, Sox3 and Oct4 during primary neurogenesis. Dev. Biol. 350 (2011), 429–440.
4. Archer, T.C., Mahoney, E.L., Pomeroy, S.L., Medulloblastoma: molecular classification-based personal therapeutics. Neurotherapeutics 14 (2017), 265–273.
5. Arnold, H.K., Zhang, X., Daniel, C.J., Tibbitts, D., Escamilla-Powers, J., Farrell, A., Tokarz, S., Morgan, C., Sears, R.C., The Axin1 scaffold protein promotes formation of a degradation complex for c-Myc. EMBO J. 28 (2009), 500–512.
6. Aryee, M.J., Jaffe, A.E., Corrada-Bravo, H., Ladd-Acosta, C., Feinberg, A.P., Hansen, K.D., Irizarry, R.A., Minfi: a flexible and comprehensive bioconductor package for the analysis of infinium DNA methylation microarrays. Bioinformatics 30 (2014), 1363–1369.
7. Barbie, D.A., Tamayo, P., Boehm, J.S., Kim, S.Y., Moody, S.E., Dunn, I.F., Schinzel, A.C., Sandy, P., Meylan, E., Scholl, C., et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462 (2009), 108–112.
8. Bigner, D.D., Bigner, S.H., Friedman, H.S., Oakes, W.J., Vogelstein, B., Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts. Cancer Res. 50 (1990), 2347–2350.
9. Brown, E.J., Frazier, W.A., Integrin-associated protein (CD47) and its ligands. Trends Cell Biol. 11 (2001), 130–135.
10. Cavalli, F.M.G., Remke, M., Rampasek, L., Peacock, J., Shih, D.J.H., Luu, B., Garzia, L., Torchia, J., Nor, C., Morrissy, A.S., et al. Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell 31 (2017), 737–754.e6.
11. Chen, Y., Olopade, O.I., MYC in breast tumor progression. Expert Rev. Anticancer Ther. 8 (2008), 1689–1698.
12. Cho, Y.-J., Tsherniak, A., Tamayo, P., Santagata, S., Ligon, A., Greulich, H., Berhoukim, R., Amani, V., Goumnerova, L., Eberhart, C.G., et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J. Clin. Oncol. 29 (2011), 1424–1430.
13. Chou, M.F., Schwartz, D., Biological sequence motif discovery using motif-x. Curr. Protoc. Bioinformatics, Chapter 13, 2011 Unit 13.15-24.
14. Cibulskis, K., Lawrence, M.S., Carter, S.L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E.S., Getz, G., Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31 (2013), 213–219.
15. Ciszewski, W.M., Tavecchio, M., Dastych, J., Curtin, N.J., DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin. Breast Cancer Res. Treat. 143 (2014), 47–55.
16. Costello, M., Pugh, T.J., Fennell, T.J., Stewart, C., Lichtenstein, L., Meldrim, J.C., Fostel, J.L., Friedrich, D.C., Perrin, D., Dionne, D., et al. Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation. Nucleic Acids Res., 41, 2013, e67.
17. Cui, F., Fan, R., Chen, Q., He, Y., Song, M., Shang, Z., Zhang, S., Zhu, W., Cao, J., Guan, H., et al. The involvement of c-Myc in the DNA double-strand break repair via regulating radiation-induced phosphorylation of ATM and DNA-PKcs activity. Mol. Cell. Biochem. 406 (2015), 43–51.
18. Davidson-Pilon, C., Kalderstam, J., Kuhn, B., Fiore-Gartland, A., Parij, A., Stark, K., Anton, S., Besson, L., and Gadgil, H. (2017). Lifelines. Survival analysis in Python. 0.11.1. https://github.com/CamDavidsonPilon/lifelines.
19. DeLuca, D.S., Levin, J.Z., Sivachenko, A., Fennell, T., Nazaire, M.D., Williams, C., Reich, M., Winckler, W., Getz, G., RNA-SeQC: RNA-seq metrics for quality control and process optimization. Bioinformatics 28 (2012), 1530–1532.
20. DePristo, M.A., Banks, E., Poplin, R., Garimella, K.V., Maguire, J.R., Hartl, C., Philippakis, A.A., del Angel, G., Rivas, M.A., Hanna, M., et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43 (2011), 491–498.
21. Diaz, R.J., Golbourn, B., Faria, C., Picard, D., Shih, D., Raynaud, D., Leadly, M., MacKenzie, D., Bryant, M., Bebenek, M., et al. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma. Oncotarget 6 (2015), 3359–3374.
22. Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., Gingeras, T.R., STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29 (2013), 15–21.
23. Edwards, N.J., Oberti, M., Thangudu, R.R., Cai, S., McGarvey, P.B., Jacob, S., Madhavan, S., Ketchum, K.A., The CPTAC data portal: a resource for cancer proteomics research. J. Proteome Res. 14 (2015), 2707–2713.
24. Farrell, A.S., Sears, R.C., MYC degradation. Cold Spring Harb. Perspect. Med., 4, 2014 a014365.
25. Forget, A., Martignetti, L., Puget, S., Calzone, L., Brabetz, S., Picard, D., Montagud, A., Liva, S., Sta, A., Dingli, F., et al. Aberrant ERBB4-SRC signaling as a hallmark of group 4 medulloblastoma revealed by integrative phosphoproteomic profiling. Cancer Cell 34 (2018), 379–395 this issue.
26. Gholamin, S., Mitra, S.S., Feroze, A.H., Liu, J., Kahn, S.A., Zhang, M., Esparza, R., Richard, C., Ramaswamy, V., Remke, M., et al. Disrupting the CD47-SIRPalpha anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. Sci. Transl. Med., 9, 2017, 10.1126/scitranslmed.aaf2968.
27. Gibson, P., Tong, Y., Robinson, G., Thompson, M.C., Currle, D.S., Eden, C., Kranenburg, T.A., Hogg, T., Poppleton, H., Martin, J., et al. Subtypes of medulloblastoma have distinct developmental origins. Nature 468 (2010), 1095–1099.
28. Hanaford, A.R., Archer, T.C., Price, A., Kahlert, U.D., Maciaczyk, J., Nikkhah, G., Kim, J.W., Ehrenberger, T., Clemons, P.A., Dančík, V., et al. DiSCoVERing innovative therapies for rare tumors: combining genetically accurate disease models with in silico analysis to identify novel therapeutic targets. Clin. Cancer Res. 22 (2016), 3903–3914.
29. Hornbeck, P.V., Zhang, B., Murray, B., Kornhauser, J.M., Latham, V., Skrzypek, E., PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res. 43 (2015), D512–D520.
30. Horvath, S., Mah, V., Lu, A.T., Woo, J.S., Choi, O.W., Jasinska, A.J., Riancho, J.A., Tung, S., Coles, N.S., Braun, J., et al. The cerebellum ages slowly according to the epigenetic clock. Aging (Albany NY) 7 (2015), 294–306.
31. Hovestadt, V., Jones, D.T., Picelli, S., Wang, W., Kool, M., Northcott, P.A., Sultan, M., Stachurski, K., Ryzhova, M., Warnatz, H.J., et al. Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. Nature 510 (2014), 537–541.
32. Huang, K.L., Li, S., Mertins, P., Cao, S., Gunawardena, H.P., Ruggles, K.V., Mani, D.R., Clauser, K.R., Tanioka, M., Usary, J., et al. Proteogenomic integration reveals therapeutic targets in breast cancer xenografts. Nat. Commun., 8, 2017, 14864.
33. Jaiswal, S., Jamieson, C.H., Pang, W.W., Park, C.Y., Chao, M.P., Majeti, R., Traver, D., van Rooijen, N., Weissman, I.L., CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 138 (2009), 271–285.
34. Janghorban, M., Farrell, A.S., Allen-Petersen, B.L., Pelz, C., Daniel, C.J., Oddo, J., Langer, E.M., Christensen, D.J., Sears, R.C., Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer. Proc. Natl. Acad. Sci. USA 111 (2014), 9157–9162.
35. Kahn, M., Can we safely target the WNT pathway?. Nat. Rev. Drug Discov. 13 (2014), 513–532.
36. Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y., Morishima, K., KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 45 (2017), D353–D361.
37. Karolchik, D., Hinrichs, A.S., Furey, T.S., Roskin, K.M., Sugnet, C.W., Haussler, D., Kent, W.J., The UCSC table browser data retrieval tool. Nucleic Acids Res. 32 (2004), D493–D496.
38. Kim, J.W., Botvinnik, O.B., Abudayyeh, O., Birger, C., Rosenbluh, J., Shrestha, Y., Abazeed, M.E., Hammerman, P.S., DiCara, D., Konieczkowski, D.J., et al. Characterizing genomic alterations in cancer by complementary functional associations. Nat. Biotechnol. 34 (2016), 539–546.
39. Kool, M., Korshunov, A., Remke, M., Jones, D.T., Schlanstein, M., Northcott, P.A., Cho, Y.J., Koster, J., Schouten-van Meeteren, A., van Vuurden, D., et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 123 (2012), 473–484.
40. Kool, M., Jones, D.T., Jager, N., Northcott, P.A., Pugh, T.J., Hovestadt, V., Piro, R.M., Esparza, L.A., Markant, S.L., Remke, M., et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell 25 (2014), 393–405.
41. Law, V., Knox, C., Djoumbou, Y., Jewison, T., Guo, A.C., Liu, Y., Maciejewski, A., Arndt, D., Wilson, M., Neveu, V., et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Res. 42 (2014), D1091–D1097.
42. Lawrence, R.T., Perez, E.M., Hernandez, D., Miller, C.P., Haas, K.M., Irie, H.Y., Lee, S.I., Blau, C.A., Villen, J., The proteomic landscape of triple-negative breast cancer. Cell Rep. 11 (2015), 630–644.
43. Li, B., Dewey, C.N., RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome. BMC Bioinformatics, 12, 2011, 323.
44. Li, H., Durbin, R., Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25 (2009), 1754–1760.
45. Liberzon, A., A description of the molecular signatures database (MSigDB) web site. Methods Mol. Biol. 1150 (2014), 153–160.
46. Liberzon, A., Birger, C., Thorvaldsdottir, H., Ghandi, M., Mesirov, J.P., Tamayo, P., The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 1 (2015), 417–425.
47. Louis, D.N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W.K., Ohgaki, H., Wiestler, O.D., Kleihues, P., Ellison, D.W., The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 131 (2016), 803–820.
48. Louis, D.N., Ohgaki, H., Wiestler, O.D., Cavenee, W.K., WHO classification of Tumours of the Central Nervous System. 2016, WHO Press.
49. Lu, A.T., Hannon, E., Levine, M.E., Hao, K., Crimmins, E.M., Lunnon, K., Kozlenkov, A., Mill, J., Dracheva, S., Horvath, S., Genetic variants near MLST8 and DHX57 affect the epigenetic age of the cerebellum. Nat. Commun., 7, 2016, 10561.
50. Ma, Y., Lu, H., Tippin, B., Goodman, M.F., Shimazaki, N., Koiwai, O., Hsieh, C.L., Schwarz, K., Lieber, M.R., A biochemically defined system for mammalian nonhomologous DNA end joining. Mol. Cell 16 (2004), 701–713.
51. McCubrey, J.A., Steelman, L.S., Bertrand, F.E., Davis, N.M., Sokolosky, M., Abrams, S.L., Montalto, G., D'Assoro, A.B., Libra, M., Nicoletti, F., et al. GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget 5 (2014), 2881–2911.
52. Mermel, C.H., Schumacher, S.E., Hill, B., Meyerson, M.L., Beroukhim, R., Getz, G., GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol., 12, 2011, R41.
53. Mertins, P., Qiao, J.W., Patel, J., Udeshi, N.D., Clauser, K.R., Mani, D.R., Burgess, M.W., Gillette, M.A., Jaffe, J.D., Carr, S.A., Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat. Methods 10 (2013), 634–637.
54. Mertins, P., Mani, D.R., Ruggles, K.V., Gillette, M.A., Clauser, K.R., Wang, P., Wang, X., Qiao, J.W., Cao, S., Petralia, F., et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534 (2016), 55–62.
55. Morrish, F., Hockenbery, D., MYC and mitochondrial biogenesis. Cold Spring Harb. Perspect. Med., 4, 2014, 10.1101/cshperspect.a014225.
56. Northcott, P.A., Hielscher, T., Dubuc, A., Mack, S., Shih, D., Remke, M., Al-Halabi, H., Albrecht, S., Jabado, N., Eberhart, C.G., et al. Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathol. 122 (2011), 231–240.
57. Northcott, P.A., Jones, D.T., Kool, M., Robinson, G.W., Gilbertson, R.J., Cho, Y.J., Pomeroy, S.L., Korshunov, A., Lichter, P., Taylor, M.D., et al. Medulloblastomics: the end of the beginning. Nat. Rev. Cancer 12 (2012), 818–834.
58. Northcott, P.A., Buchhalter, I., Morrissy, A.S., Hovestadt, V., Weischenfeldt, J., Ehrenberger, T., Gröbner, S., Segura-Wang, M., Zichner, T., Rudneva, V.A., et al. The whole-genome landscape of medulloblastoma subtypes. Nature, 547, 2017, 10.1038/nature22973.
59. Obenauer, J.C., Cantley, L.C., Yaffe, M.B., Scansite 2.0: proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res. 31 (2003), 3635–3641.
60. Pei, Y., Liu, K.W., Wang, J., Garancher, A., Tao, R., Esparza, L.A., Maier, D.L., Udaka, Y.T., Murad, N., Morrissy, S., et al. HDAC and PI3K antagonists cooperate to inhibit growth of MYC-driven medulloblastoma. Cancer Cell 29 (2016), 311–323.
61. Pfister, S., Remke, M., Benner, A., Mendrzyk, F., Toedt, G., Felsberg, J., Wittmann, A., Devens, F., Gerber, N.U., Joos, S., et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J. Clin. Oncol. 27 (2009), 1627–1636.
62. Pozo, K., Bibb, J.A., The emerging role of Cdk5 in cancer. Trends Cancer 2 (2016), 606–618.
63. Pugh, T.J., Weeraratne, S.D., Archer, T.C., Pomeranz Krummel, D.A., Auclair, D., Bochicchio, J., Carneiro, M.O., Carter, S.L., Cibulskis, K., Erlich, R.L., et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 488 (2012), 106–110.
64. Ramos, A.H., Lichtenstein, L., Gupta, M., Lawrence, M.S., Pugh, T.J., Saksena, G., Meyerson, M., Getz, G., Oncotator: cancer variant annotation tool. Hum. Mutat. 36 (2015), E2423–E2429.
65. Rauniyar, N., Yates, J.R. 3rd, Isobaric labeling-based relative quantification in shotgun proteomics. J. Proteome Res. 13 (2014), 5293–5309.
66. Razick, S., Magklaras, G., Donaldson, I.M., iRefIndex: a consolidated protein interaction database with provenance. BMC Bioinformatics, 9, 2008, 405.
67. Robinson, G., Parker, M., Kranenburg, T.A., Lu, C., Chen, X., Ding, L., Phoenix, T.N., Hedlund, E., Wei, L., Zhu, X., et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 488 (2012), 43–48.
68. Robinson, G.W., Orr, B.A., Wu, G., Gururangan, S., Lin, T., Qaddoumi, I., Packer, R.J., Goldman, S., Prados, M.D., Desjardins, A., et al. Vismodegib exerts targeted efficacy against recurrent sonic hedgehog-subgroup medulloblastoma: results from phase II pediatric brain tumor consortium studies PBTC-025B and PBTC-032. J. Clin. Oncol. 33 (2015), 2646–2654.
69. Schwalbe, E.C., Lindsey, J.C., Nakjang, S., Crosier, S., Smith, A.J., Hicks, D., Rafiee, G., Hill, R.M., Iliasova, A., Stone, T., et al. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. Lancet Oncol. 18 (2017), 958–971.
70. Senbabaoglu, Y., Michailidis, G., Li, J.Z., Critical limitations of consensus clustering in class discovery. Sci. Rep., 4, 2014, 6207.
71. Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., Amin, N., Schwikowski, B., Ideker, T., Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13 (2003), 2498–2504.
72. Staal, J.A., Lau, L.S., Zhang, H., Ingram, W.J., Hallahan, A.R., Northcott, P.A., Pfister, S.M., Wechsler-Reya, R.J., Rusert, J.M., Taylor, M.D., et al. Proteomic profiling of high risk medulloblastoma reveals functional biology. Oncotarget 6 (2015), 14584–14595.
73. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102 (2005), 15545–15550.
74. Sunada, S., Kanai, H., Lee, Y., Yasuda, T., Hirakawa, H., Liu, C., Fujimori, A., Uesaka, M., Okayasu, R., Nontoxic concentration of DNA-PK inhibitor NU7441 radio-sensitizes lung tumor cells with little effect on double strand break repair. Cancer Sci. 107 (2016), 1250–1255.
75. Tamayo, P., Cho, Y.-J., Tsherniak, A., Greulich, H., Ambrogio, L., Schouten-van Meeteren, N., Zhou, T., Buxton, A., Kool, M., Meyerson, M., et al. Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features. J. Clin. Oncol. 29 (2011), 1415–1423.
76. Taylor, M.D., Northcott, P.A., Korshunov, A., Remke, M., Cho, Y.J., Clifford, S.C., Eberhart, C.G., Parsons, D.W., Rutkowski, S., Gajjar, A., et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 123 (2012), 465–472.
77. Tuncbag, N., Gosline, S.J., Kedaigle, A., Soltis, A.R., Gitter, A., Fraenkel, E., Network-based interpretation of diverse high-throughput datasets through the omics integrator software package. PLoS Comput. Biol., 12, 2016, e1004879.
78. Wagih, O., Sugiyama, N., Ishihama, Y., Beltrao, P., Uncovering phosphorylation-based specificities through functional interaction networks. Mol. Cell. Proteomics 15 (2016), 236–245.
79. Wang, X., Cunningham, M., Zhang, X., Tokarz, S., Laraway, B., Troxell, M., Sears, R.C., Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland. Cancer Res. 71 (2011), 925–936.
80. Weeraratne, S.D., Amani, V., Teider, N., Pierre-Francois, J., Winter, D., Kye, M.J., Sengupta, S., Archer, T., Remke, M., Bai, A.H., et al. Pleiotropic effects of miR-183∼96∼182 converge to regulate cell survival, proliferation and migration in medulloblastoma. Acta Neuropathol. 123 (2012), 539–552.
81. Wilkerson, M.D., Hayes, D.N., ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 26 (2010), 1572–1573.
82. Zhang, B., Wang, J., Wang, X., Zhu, J., Liu, Q., Shi, Z., Chambers, M.C., Zimmerman, L.J., Shaddox, K.F., Kim, S., et al. Proteogenomic characterization of human colon and rectal cancer. Nature 513 (2014), 382–387.
83. Zhang, H., Meltzer, P., Davis, S., RCircos: an R package for Circos 2D track plots. BMC Bioinformatics, 14, 2013, 244.
84. Zhang, H., Liu, T., Zhang, Z., Payne, S.H., Zhang, B., McDermott, J.E., Zhou, J.Y., Petyuk, V.A., Chen, L., Ray, D., et al. Integrated proteogenomic characterization of human high-grade serous ovarian cancer. Cell 166 (2016), 755–765.
85. Zhang, X., Farrell, A.S., Daniel, C.J., Arnold, H., Scanlan, C., Laraway, B.J., Janghorban, M., Lum, L., Chen, D., Troxell, M., et al. Mechanistic insight into Myc stabilization in breast cancer involving aberrant Axin1 expression. Proc. Natl. Acad. Sci. USA 109 (2012), 2790–2795.